摘要
目的:探讨麻芥平喘巴布剂在细胞水平对Ⅰ型变态反应所引起的支气管哮喘的疗效机制。方法:用MTT比色法测定不同浓度麻芥平喘提取物对RBL-2H3细胞活化增殖的影响。根据MTT比色法结果选择麻芥平喘提取物5个不同的实验浓度,阳性对照组选用色甘酸钠。以C48/80刺激RBL-2H3细胞活化脱颗粒。通过ELISA法检测不同浓度药物对致敏的RBL-2H3细胞活化脱颗粒释放TNF-α及组胺的影响。结果:高浓度麻芥平喘提取物对RBL-2H3细胞增殖有抑制作用,IC50值为7.5 mg/m L。较高浓度麻芥平喘提取物可抑制激活的RBL-2H3细胞释放TNF-α和组胺,且其抑制作用强于色甘酸钠0.1 mg/m L组。RBL-2H3细胞激活后释放TNF-α抑制率与麻芥平喘提取物浓度的对数呈正相关(P=0.002<0.01)。结论:麻芥平喘巴布剂提取物可有效抑制经C48/80激活的RBL-2H3细胞脱颗粒释放TNF-α及组胺,这可能是麻芥平喘巴布剂抑制哮喘I型变态反应的机制之一。
Objective: To discuss the direct effect of Majie-Pingchuan Cataplasma extractive on bronchial asthma caused by type-I allergy at the cellular level. Methods: The influence of Majie-Pingchuan Cataplasma extractive at different concentrations on proliferation of RBL-2H3 mast cells was determined with MTT colori- metric assy. The five different concentrations of Majie-Pingchuan Cataplasma extractive were selected according to the results from MTT colorimetric assay and cromolyn sodium was applied in the positive control group. Pre- treated RBL-2H3 cells with different dilutions of Majie-Pingchuan Cataplasma extractive and sodium cromogli- cate were activated by compound C48/80.The tumor necrosis factor-alpha (TNF-α) from the supernatants, the spontaneously released histamine and the total histamine were measured by ELISA. Results: High concentrations of Majie-Pingchuan Cataplasma extractive suppressed the proliferation of RBL-2H3 mast cells and the IC50 was 7.5 mg/mL. The higher concentrations groups showed inhibition on TNF-~x released from RBL-2H3 mast cells and the effect was comparable to cromolyn sodium control group (0.1 mg/mL). The suppressed percentage of TNF-α was positively correlated with the concentration of Majie-Pingchuan Cataplasma extractive (P=0.002〈0.01). Conclusion: Majie-Pingchuan Cataplasma extractive can inhibit the degranulation of RBL-2H3 cells activated by compound C48/80, which maybe one of the mechanisms of type- I anti-allergic reaction in the treatment of bronchial asthma by Majie-Pingchuan Cataplasma.
出处
《中医药导报》
2016年第13期11-13,20,共4页
Guiding Journal of Traditional Chinese Medicine and Pharmacy
基金
科技部重大新药创制(No.2012ZX09103201-007)